CNSL.LSE Cambridge Nutritional Sciences plc
- Market cap
- GBX 3.69M
- P/E
- -
- P/B
- 0.65x
- ROE
- -102.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is CNSL.LSE undervalued?
Graham numberThe Graham number of Cambridge Nutritional Sciences plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cambridge Nutritional Sciences plc fundamental analysis
No fundamental analysis for Cambridge Nutritional Sciences plc yet.
Cambridge Nutritional Sciences plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market in the United Kingdom, rest of Europe, the Americas, India, rest of Asia and the Far East, Africa, and the Middle East. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis t…
Full company profileCambridge Nutritional Sciences plc financial statements
Cambridge Nutritional Sciences plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.2M | 8.33M | 8.76M | 9.82M | 6.82M | 8.54M | 7.55M | 9.77M | 8.33M | 6.98M |
| Gross Profit | 9.22M | 5.48M | 5.63M | 6.29M | 4.00M | 4.75M | 3.17M | 6.05M | 5.01M | 4.28M |
| Operating Income | 695K | -1.44M | -271K | -8.05M | -488K | -582K | -2.78M | -535K | -640K | -1.04M |
| EBITDA | 1.29M | -816K | 202K | -6.89M | 418K | 360K | -2.65M | -73.0K | 2.20M | -392K |
| Net Income | 713K | -7.27M | 974K | -6.83M | -2.10M | -11.3M | -3.86M | -328K | 1.57M | -5.83M |
| EPS | 0.01 | -0.06 | 0.01 | -0.05 | -0.01 | -0.06 | -0.02 | 0.00 | 0.01 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 25.8M | 22.9M | 23.5M | 18.8M | 29.5M | 17.8M | 14.4M | 13.9M | 13.8M | 7.45M |
| Total Liabilities | 4.30M | 5.78M | 5.28M | 5.23M | 6.16M | 6.02M | 4.45M | 4.21M | 2.39M | 1.77M |
| Shareholders' Equity | 21.5M | 17.1M | 18.2M | 13.6M | 23.4M | 11.8M | 9.95M | 9.68M | 11.4M | 5.68M |
| Cash & Short-term Investments | 737K | 116K | - | - | 5.83M | 1.61M | 5.12M | 5.44M | 4.87M | 2.64M |
| Total Debt | 863K | 883K | 922K | 2.57M | 452K | 370K | 74.0K | 148K | 349K | 125K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.01M | -828K | 369K | 548K | -2.42M | -3.23M | -3.15M | 607K | 83.0K | -1.13M |
| Capital Expenditure | 2.66M | 3.28M | 2.69M | 2.15M | 2.83M | 1.48M | 153K | 59.0K | 225K | 253K |
| Free Cash Flow | -649K | -4.11M | -2.33M | -1.61M | -5.24M | -4.71M | -3.31M | 548K | -142K | -1.39M |
| Ratios | ||||||||||
| ROE | 3.3% | -42.5% | 5.4% | -50.2% | -9.0% | -95.9% | -38.8% | -3.4% | 13.7% | -102.6% |
| ROA | 2.8% | -31.7% | 4.2% | -36.3% | -7.1% | -63.5% | -26.8% | -2.4% | 11.3% | -78.2% |
| Net Profit Margin | 5.0% | -87.3% | 11.1% | -69.5% | -30.9% | -132.7% | -51.2% | -3.4% | 18.8% | -83.5% |
| Debt to Equity | 0.04x | 0.05x | 0.05x | 0.19x | 0.02x | 0.03x | 0.01x | 0.02x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cambridge Nutritional Sciences plc dividends
Cambridge Nutritional Sciences plc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:40 on Aug 31, 2007.
Who owns Cambridge Nutritional Sciences plc
- Insiders 31.10%
- Institutions 4.60%
- Public & others 64.30%
- Shares outstanding 238M
- Free float 180M
Cambridge Nutritional Sciences plc company profile
- Company name
- Cambridge Nutritional Sciences plc
- Ticker
- CNSL.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 85
- Fiscal year end
- March
- Address
- One Fleet Place, London, United Kingdom, EC4M 7WS
- Website
- cnsplc.com
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market in the United Kingdom, rest of Europe, the Americas, India, rest of Asia and the Far East, Africa, and the Middle East. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis to the public, clinics, and health professionals; and supplies Food Detective, a food sensitivity test. In addition, the company offers Gut Detective, a comprehensive stool biomarker panel used to investigate key areas of gut health, including inflammation, digestive enzyme production and intestinal permeability; and CNS Lab, which provides laboratory services for food sensitivity. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc is based in London, the United Kingdom.
Cambridge Nutritional Sciences plc management
6- Mr. James Cooper B.A., M.Sc.CEO & Executive Director · born 1991
- Mr. Ajay Patel A.C.A., L.L.B.CFO, Secretary & Executive Director · born 1964
- Mr. Iain Alexander James LoganGroup Financial Controller · born 1973
- Mr. Prashant ManiarManaging Director of Omega Dx Asia Pvt Limited
- Motunrayo OyegunleSecretary
- Mr. Andrew William Shepherd BSc.(Hons)Global Ambassador - Life President · born 1956